Sequre Inc
Total Consideration
$2.3M
Purchase-Price Allocation
Goodwill
$3.9M
Intangibles
$508.0K
Contingent Earn-Out
$25.0K
Pro-Forma Combined Entity
Revenue
$33.2M
Net Income
−$46.5M
Diluted EPS
$-0.44
MAXCYTE, INC. — Key Metrics
2 years of history · ending 2025-12-31 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
Z-Score (Altman; <1.81 = distress)
Per Share Metrics
Turnover & Efficiency Analysis (days)
Expense Ratios
Working Capital Analysis
Valuation Multiples
Enterprise Value Multiples
52-Week Range
Trailing Returns
ROIC vs WACC
Yields
Capital Deployment Yields
Liquidity & Leverage Ratios
Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)
EPS (Diluted)
$-0
Book Value Per Share
$2
Free Cash Flow Per Share
$-0
Cash Per Share
$0
Revenue Per Share
$0
OCF Per Share
$-0
Return on Equity
-23.6%
Return on Assets
-20.2%
Return on Invested Capital
-21.7%
Current Ratio
8.30
Quick Ratio
7.77
Asset Turnover
0.15
Days Sales Outstanding
38.71
Days Payables Outstanding
82.19
Days Inventory On Hand
442.73
Cash Conversion Cycle
399.26
R&D / Revenue
63.1%
SBC / Revenue
27.9%
Capex / Revenue
5.4%
Working Capital
$104M
Net Current Asset Value
$87M
Invested Capital
$171M
OCF / Net Income
0.77
FCF / Net Income
0.81
Accruals Ratio (Sloan)
-5.0%
Net Debt
$-103M
Net Debt / EBITDA
2.17
Interest Coverage
—
Cash Coverage
—
Capex Coverage
-19.46
Tangible Common Equity
$171M
TCE / Total Assets
84.4%
NOPAT
$-41M
Cash ROIC
-19.2%
WC / Revenue
315.2%
Capex / D&A
0.41
Reinvestment Rate
1.5%
Asset Growth vs Revenue Growth
-0.9%
Revenue 5Y CAGR
4.8%
Book Value 5Y CAGR
38.9%
Stock Price (FY-end)
$2
Market Cap
$165M
P/S Ratio
4.99
P/B Ratio
0.96
P/TB Ratio
0.97
Enterprise Value
$62M
EV / Sales
1.87
FCF Yield
-21.9%
Shareholder Yield
-5.6%
R&D Yield
12.6%
Capex Yield
1.1%
Shares Variation (YoY)
1.5%
Beta (5Y)
1.45
Cost of Equity
11.7%
52W High
$5
52W Low
$1
Trailing Return 1Y
-62.5%
F-Score (Piotroski)
2.00
Z-Score (Altman)
1.32
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
EPS — Consensus vs Actual
Revenue — Consensus vs Actual
Stock Price on Earnings Dates
MAXCYTE, INC. — Effective Tax Rate ReconciliationNEW
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
| Reconciliation Line | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Federal Statutory Rate | 21.00% | 21.00% | 21.00% |
| State & Local Income Taxes | — | — | — |
| Foreign Rate Differential | — | — | — |
| Other Adjustments | — | — | — |
| SBC (Nondeductible) | — | -1.00% | -1.80% |
| Valuation Allowance Change | — | -19.10% | -27.90% |
| Effective Tax Rate | — | — | — |
Cash vs Accrual
| Item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Income Tax Expense (Accrual) | — | — | — |
| Income Taxes Paid (Cash) | — | — | — |
MAXCYTE, INC. — M&A AcquisitionsNEW
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.